33564-30-6
33564-30-6
Chemical Structure
Cefoxitin sodium
Synonym(s): MK-306
- CAS No.: 33564-30-6
- Formula:C16H16N3NaO7S2
- Molecular Weight:449.43
IUPAC Name: sodium (6R,7S)-3-((carbamoyloxy)methyl)-7-methoxy-8-oxo-7-(2-(thiophen-2-yl)acetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
InChIKey: GNWUOVJNSFPWDD-XMZRARIVSA-M
SMILES: O=C(C(N12)=C(COC(N)=O)CS[C@]2([H])[C@@](NC(CC3=CC=CS3)=O)(OC)C1=O)O[Na]
Biological Activity: Cefoxitin sodium (MK-306) is a cephalosporin-class antibiotic. Cefoxitin sodium is highly stable against β-Lactamase (HY-P2998). Cefoxitin sodium has a broad spectrum of antibacterial activity, including Gram-negative and Gram-positive bacteria[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cefoxitin sodium | 99.69% | Cefoxitin sodium (MK-306) is a cephalosporin-class antibiotic. Cefoxitin sodium is highly stable against β-Lactamase (HY-P2998). Cefoxitin sodium has a broad spectrum of antibacterial activity, including Gram-negative and Gram-positive bacteria. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cefoxitin sodium (Standard) | 98.82% | Cefoxitin sodium (Standard) is the analytical standard of Cefoxitin sodium. This product is intended for research and analytical applications. Cefoxitin sodium is a cephalosporin-class antibiotic. Cefoxitin sodium is highly stable against β-Lactamase (HY-P2998). Cefoxitin sodium has a broad spectrum of antibacterial activity, including Gram-negative and Gram-positive bacteria. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Cavalli Z, et al. Prolonged Cefoxitin Infusion Using Mobile Elastomeric Infusors In Outpatients With Bone And Joint Infection. J Bone Jt Infect. 2018 Sep 7;3(4):182-186. [Content Brief]
- [2]. R N Brogden, et al. Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1979 Jan;17(1):1-37. [Content Brief]
- [3]. Venkata Raveendra Pothineni, et al. In vitro and in vivo evaluation of cephalosporins for the treatment of Lyme disease. Drug Des Devel Ther. 2018; 12: 2915–2921. [Content Brief]
